Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SUPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SUPN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Supernus Pharmaceuticals Inc

SUPN
Current price
32.34 USD -1.49 USD (-4.40%)
Last closed 33.59 USD
ISIN US8684591089
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 810 703 616 USD
Yield for 12 month +7.80 %
1Y
3Y
5Y
10Y
15Y
SUPN
21.11.2021 - 28.11.2021

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. Address: 9715 Key West Avenue, Rockville, MD, United States, 20850

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

39.00 USD

P/E Ratio

29.14

Dividend Yield

Financials SUPN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SUPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+661 817 000 USD

Last Year

+607 521 000 USD

Current Quarter

+149 824 000 USD

Last Quarter

+174 159 000 USD

Current Year

+583 911 000 USD

Last Year

+523 742 000 USD

Current Quarter

+134 061 000 USD

Last Quarter

+129 216 000 USD
EBITDA 138 656 000 USD
Operating Margin TTM -4.67 %
Price to Earnings 29.14
Return On Assets TTM 2.76 %
PEG Ratio 1.47
Return On Equity TTM 6.32 %
Wall Street Target Price 39.00 USD
Revenue TTM 667 996 992 USD
Book Value 18.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.30 %
Dividend Yield
Gross Profit TTM 590 636 992 USD
Earnings per share 1.11 USD
Diluted Eps TTM 1.11 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 1 444.70 %
Profit Margin 9.27 %

Stock Valuation SUPN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 29.14
Forward PE 20.16
Enterprise Value Revenue 2.20
Price Sales TTM 2.71
Enterprise Value EBITDA 8.05
Price Book MRQ 1.82

Technical Indicators SUPN

For 52 Weeks

27.05 USD 40.28 USD
50 Day MA 32.30 USD
Shares Short Prior Month 4 029 853
200 Day MA 34.06 USD
Short Ratio 8.64
Shares Short 4 897 876
Short Percent 10.26 %